DENKI KAGAKU KOGYO KABUSHIKI KAISHA (Headquartered at: Chuo-ku, Tokyo; Shinsuke Yoshitaka, President & CEO, hereinafter ”Denka”) is pleased to announce that, it has agreed and entered into a share transfer agreement on August 6, 2015 with Nomad Bioscience GmbH (Headquartered at: Munich, Germany; Prof. Dr. Yuri Gleba, CEO, hereinafter ”Nomad”) regarding its acquisition (the ”Acquisition”)… Read more »
Month: April 2017
Icon Genetics successfully completes Phase I clinical study with personalized vaccines for treatment of non-Hodgkin’s lymphoma
Icon Genetics GmbH (ICON) successfully completed a Phase I clinical study on the safety and immunogenicity of personalized vaccines to treat patients with follicular non-Hodgkin’s lymphoma. The vaccines, which consist of monoclonal antibodies derived from each patient’s own tumor and serve as disease-specific markers, were administered to induce a tumor-specific immune reaction. The vaccines were… Read more »
Icon Genetics and Bayer CropScience successfully completed the development of a plant host system with designer glycosylation needed for manufacturing biopharmaceuticals in green plants
Icon Genetics GmbH, Munich, Germany (ICON) and Bayer CropScience have successfully created a novel plant host system for the production of biopharmaceuticals. Bayer has delivered a Nicotiana plant that is deficient in plant-specific sugar residues resulting in different plant glycosylation patterns. The plant host is already being used by ICON as a new component in… Read more »
Icon Genetics’ personalized vaccine clinical trials is featured in documentary series from Baylor Health Care System
A three-part documentary series with participation of patients involved in Phase I clinical trials of Icon’s Non-Hodgkin’s Lymphoma personalized vaccine was recently released for public view. Full documentary can be seen at http://www.baylorhealth.com/dallashope/pages/default.aspx.
Icon Genetics to Provide John Innes Centre Access to Golden Gate Cloning Platform
Munich, September 20, 2012 — Icon Genetics GmbH (ICON), Munich/Halle, Germany, has announced that the Company has entered into a license agreement with the Sainsbury Laboratory (TSL) and the John Innes Centre (JIC), Norwich, UK, that allows TSL and JIC to use in its research ICON’s high-throughput DNA Assembly Platform known as ‘Golden Gate Cloning’.… Read more »
CSIR gets free access to Icon Genetics manufacturing technology
Johannesburg, 16 July 2012 — The Council for Scientific and Industrial Research and ICON, Munich/Halle, Germany, have announced that they have entered into an agreement that will allow the CSIR to make use of its plant-based manufacturing platform known as ‘magnICON®’ for research and development (R&D) and royalty-free manufacturing of rabies vaccines and post-exposure prophylaxis… Read more »
Frost & Sullivan’s to recognize Icon Genetics with the 2012 European Technology Innovation Award.
Icon Genetics GmbH (ICON), Munich/Halle, Germany, a plant biotechnology company, has announced that the Company has been awarded a prestigious Frost & Sullivan European Technology Innovation Award. For the Technology Innovation Award, the following criteria were used to benchmark Icon Genetics’ performance against key competitors: uniqueness of the technology; impact on new products/applications; impact on… Read more »
Icon Genetics and Bayer CropScience sign an agreement to develop production hosts with designer glycosylation
Munich, May 09, 2012 — Icon Genetics GmbH, Munich, Germany (ICON) and Bayer CropScience have entered into a contract development agreement to create novel plant production hosts for biopharmaceuticals. The aim of the agreement is to develop manufacturing hosts with a designer glycosylation, in particular, humanized glycosylation. Such hosts with modified glycosylation of recombinant proteins… Read more »
Kentucky Bioprocessing, Icon Genetics and Mapp Biopharmaceutical have entered into discussions to merge their businesses
OWENSBORO, Kentucky (USA), SAN DIEGO, California (USA) and MUNICH (Germany), May 07, 2012 — Kentucky Bioprocessing, LLC (KBP), Icon Genetics, GmbH (ICON) and Mapp Biopharmaceutical, Inc. (Mappbio) have announced that they have entered into detailed negotiations aimed at merging the companies to create a single, fully integrated biopharmaceutical discovery, development and manufacturing enterprise. While many… Read more »
Recent Comments